Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tibet Rhodiola Capsule is a traditional Chinese herbal medicine (botanical) being investigated for the treatment of mild to moderate obstructive sleep apnea (OSA). Derived from the *Rhodiola* plant (likely *Rhodiola rosea*), the formulation contains bioactive compounds such as salidroside, tyrosol, and ethyl gallate. These components are known for their antioxidant, anti-inflammatory, and neuroprotective properties. In the context of OSA, the drug is hypothesized to mitigate intermittent hypoxia-induced oxidative stress and systemic inflammation, potentially reducing cardiovascular risk factors. Clinical evaluation, led by Dr. Shao-Ping Nie at Beijing Anzhen Hospital, focuses on its ability to improve oxygen saturation and markers of oxidative stress like superoxide dismutase (SOD) and malondialdehyde (MDA) in patients who refuse continuous positive airway pressure (CPAP) therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tibet Rhodiola Capsule.